Usage of Electronic Signatures-Notification to Regulatory [Software]

posted by Debbie – India, 2010-09-29 11:49 (5320 d 14:51 ago) – Posting: # 5954
Views: 4,062

Hi,

Is the usage of electronic signatures in Nugenesis SDMS (for bioanalytical data of Bioequivalence study) needs to be notified to FDA and other regulatory authorities before/after start of usage.

As per 21 CFR Part 11 section 11.100 (c), the usage of electronic signatures to be notified to FDA.

Is the requirement applies to electronic signatures of Nugenesis SDMS for the handling of bioanalytical chromatographic data?

Is there any similar requirement from other regulatory regions like EMA, TGA Canada etc.

please provide your valuable inputs.

Regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
31 visitors (0 registered, 31 guests [including 6 identified bots]).
Forum time: 02:40 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5